{"id":"W4308963956","doi":"10.1097/hs9.0000000000000801","title":"Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"Janssen Biotech; Novo Nordisk; Ascentage Pharma; Servier; Moderna; Celltrion; Incyte; Pharmacyclics; MEI Pharma; Karyopharm Therapeutics; Gilead Sciences; BeiGene; Sanofi; Cilag; TG Therapeutics; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Bendamustine; Chronic lymphocytic leukemia; Tolerability; Ofatumumab; Gastroenterology; Adverse effect; Oncology; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003067108,0.00103748,0.001298889,0.00037114,0.0003578707,0.001039945,0.0007106491,0.0009222742,0.003835111],"category_scores_gemma":[0.002181548,0.000201818,0.001642543,0.0003246769,0.0005380264,0.0009178388,0.000377803,0.002539306,0.0006079681],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006446535,"about_ca_system_score_gemma":0.000706516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006558932,"about_ca_topic_score_gemma":0.002261044,"domain_scores_codex":[0.9991634,0.00054248,0.00003450468,0.00007159763,0.0000731846,0.0001148918],"domain_scores_gemma":[0.9989391,0.0003323964,0.0002015089,0.00008727877,0.00008398819,0.0003557499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8855607,0.006466113,0.003724333,0.001035167,0.002232442,0.0001722892,0.0001442167,0.001795203,0.004512187,0.0006612543,0.0165035,0.07719271],"study_design_scores_gemma":[0.840817,0.1182586,0.01597054,0.0002089974,0.002174356,0.0003635179,0.00008014902,0.003222905,0.002110235,0.001356306,0.01537998,0.00005737527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9603305,0.01568561,0.0007085351,0.001917869,0.000449362,0.001669215,0.004795744,0.0002325124,0.01421063],"genre_scores_gemma":[0.9771673,0.004404396,0.001463859,0.001791099,0.0006708811,0.001745425,0.008030199,0.00004569707,0.004681114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003835111,"threshold_uncertainty_score":0.01622063,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07152014511977556,"score_gpt":0.3352977625918449,"score_spread":0.2637776174720693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}